Valiant Laboratories (NSE:VALIANTLAB) Operating Income: ₹4 Mil (TTM As of Mar. 2026)


NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
58 GF Score
Price ₹65.51
GF Value ₹102.61
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Valiant Laboratories Operating Income?

Valiant Laboratories NSE:VALIANTLAB +0.77% 58 Operating Income is ₹4 Mil as of Mar. 2026. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 58/100 and a GF Value™ of ₹102.61 (Possible Value Trap). The stock has 5 warning signs investors should review.

Valiant Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Valiant Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹19 Mil. Valiant Laboratories's Revenue for the three months ended in Mar. 2026 was ₹920 Mil. Therefore, Valiant Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 was 2.05%.

Valiant Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Valiant Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 2.24%. Valiant Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.52%.

Valiant Laboratories  (NSE:VALIANTLAB) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Valiant Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=75.476 * ( 1 - 0% )/( (0 + 3368.023)/ 1 )
=75.476/3368.023
=2.24 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4639.766 - 940.248 - ( 331.495 - max(0, 1194.458 - 2283.234+331.495))
=3368.023

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Valiant Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=82.316/( ( (0 + max(0, 0)) + (2330.989 + max(930.074, 0)) )/ 1 )
=82.316/( ( 0 + 3261.063 )/ 1 )
=82.316/3261.063
=2.52 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(935.648 + 454.262 + 561.41) - (940.248 + 0 + 80.998)
=930.074

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Valiant Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=18.869/919.818
=2.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Valiant Laboratories Operating Income Related Terms

Valiant Laboratories Operating Income Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Operating Income Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Income
Get a 7-Day Free Trial 400.05 335.83 -103.75 -67.72 3.50

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.08 18.67 -4.54 -29.36 18.87
NSE:VALIANTLAB
58GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹4 Mil mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Operating Income of ₹4 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Valiant Laboratories and its competitors.
Is Valiant Laboratories' Operating Income too high?
Valiant Laboratories' current Operating Income is ₹4 Mil. Overall, Valiant Laboratories has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Operating Income compare to ZTS and UTHR?
Valiant Laboratories' Operating Income of ₹4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Valiant Laboratories and its competitors. Valiant Laboratories's current Operating Income is ₹4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.61, compared to a current price of ₹65.51 — trading 36.2% below its estimated fair value. The current Operating Income is ₹4 Mil. Valiant Laboratories' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Operating Income is ₹4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹65.51 is trading 36.2% below its estimated GF Value™ of ₹102.61. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • Operating Income: ₹4 Mil
  • GF Value™: ₹102.61 vs. price of ₹65.51 (36.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
58GF Score

Get the complete analysis for NSE:VALIANTLAB

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹65.51
Price
₹102.61
GF Value